CAJ | 학술논문

目的观察环磷酰胺对大鼠生精功能的影响.方法 8周龄成年雄性sD大鼠,分6组,每组16只.前5组为实验组,给药方法分别为每日10、20、40、80、100 mg/kg,另1组为对照组.胃管给药2周和4周后,处死大鼠,取附睾精子行CASA检查;取睾丸组织苏木素.伊红(HE)染色分析睾丸曲细精管结构变化,TUNEL法检测睾丸曲细精管细胞凋亡情况.留取血清标本采用电化学发光法检测性激索水平.结果环磷酰胺每日40 mg/kg喂养4周,大鼠存活率93.8%,精子数量明显减少(29.36±8.64)X 106个/ml,精子活力降低(22.25±2.03)%,睾丸生精上皮细胞明显损伤变性(58.1±1.2)%,血清睾酮水平下降(0.149±0.020)μg/L.这些指标的变化与环磷酰胺给药剂量及时间旱负相关(P<0.05).结论通过环磷酰胺诱导可以成功建立大鼠少精/无精症动物模型,环磷酰胺主要通过坏死和凋亡两种途径导致睾丸曲细精管结构变化,导致生精细胞减少并最终引起少精/无精症.
목적 관찰배린선알대대서생정공능적영향.방법 8주령성년웅성sD대서,분6조,매조16지.전5조위실험조,급약방법분별위매일10、20、40、80、100 mg/kg,령1조위대조조.위관급약2주화4주후,처사대서,취부고정자행CASA검사;취고환조직소목소.이홍(HE)염색분석고환곡세정관결구변화,TUNEL법검측고환곡세정관세포조망정황.류취혈청표본채용전화학발광법검측성격색수평.결과 배린선알매일40 mg/kg위양4주,대서존활솔93.8%,정자수량명현감소(29.36±8.64)X 106개/ml,정자활력강저(22.25±2.03)%,고환생정상피세포명현손상변성(58.1±1.2)%,혈청고동수평하강(0.149±0.020)μg/L.저사지표적변화여배린선알급약제량급시간한부상관(P<0.05).결론 통과배린선알유도가이성공건립대서소정/무정증동물모형,배린선알주요통과배사화조망량충도경도치고환곡세정관결구변화,도치생정세포감소병최종인기소정/무정증.
Objective To evaluate the effect of cyclophosphamide on spermatogenic function in rats. Methods Ninty-six male adult SD rats (8 weeks old) were equally divided into 6 groups. Different in A-E groups. The last group served as control. 14-28 days after the administration of the drug via the gas-tric tube, the rats were sacrificed, and their sperms taken from the epididymis were examimined with the techniques of CASA. The structural changes in the convoluted seminiferous tubules of their testis were pathologically studied by HE staining, and apoptosis of the cells of these tubules was detected by the TUNEL method. The sexual hormone levels in the serum of these animals were also tested. Results After sperms were reduced by (29.36±8.64) x 106/ml, sperm viability was decreased by(22.25±2.03)%, the testis germ cells were obviously damaged and degenerated, and levels of sexual hormone was declined to (0. 149±0.020) μg/L. All these changes were negatively correlated with the does and time of cyclo-phosphamide(P < 0. 05 ). Conclusion Models of oligoazoospermia/azoospermia could successfully estab-hshed in rats following the administration of cyclophosphamide.